Dabigatran/Diltiazem Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
When these two medicines are taken together, your body may not process dabigatran properly.
What might happen:
Your blood levels of dabigatran may increase. This may cause serious bleeding.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want to change your blood thinner. Let your healthcare professional know if the side effects of your medicine increase or if you have any bleeding from the eyes, gums or nose; unusual bruising; dark stools; red or dark brown urine; and/or abdominal pain or swelling.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop or change the dosage of any medication before checking with them first.
- 1.Pradaxa (dabigatran etexilate mesylate) US prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc. June, 2021.
- 2.Pradax (dabigatran etexilate mesilate) Canadian prescribing information. Boehringer Ingelheim March, 23 2020.
- 3.Pradaxa (dabigatran etexilate mesilate) UK summary of product characteristics. Boehringer Ingelheim Limited January 10, 2020.
- 4.Anonymous. FDA Dabigatran background package for Cardio-Renal Advisory Committee. available at http://wayback.archive-it.org/7993/20170405212218/https://www.fda.gov/down loads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Cardiovascularan dRenalDrugsAdvisoryCommittee/UCM247244.pdf September 20, 2010.
- 5.Pham P, Schmidt S, Lesko L, Lip GYH, Brown JD. Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney Function. JAMA Netw Open;3(4)(2574-3805 (Electronic). 2574-3805 (Linking)):.
- 6.Wiggins BS, Dixon DL, Neyens RR, Page RL 2nd, Gluckman TJ. Select Drug-Drug Interactions With Direct Oral Anticoagulants: JACC Review Topic of the Week..
- 7.Xu Y, Chang AR, Inker LA, McAdams-DeMarco M, Grams ME, Shin JI. Concomitant Use of Diltiazem With Direct Oral Anticoagulants and Bleeding Risk in Atrial Fibrillation. J Am Heart Assoc 2022 Jul 19;11(14):e025723.
- 8.Chang SH, Chou IJ, Yeh YH, Chiou MJ, Wen MS, Kuo CT, See LC, Kuo CF. Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation. JAMA 2017 Oct 3;318(13):1250-1259.
- 9.Hill K, Sucha E, Rhodes E, Bota S, Hundemer GL, Clark EG, Canney M, Harel Z, Wang TF, Carrier M, Wijeysundera HC, Knoll G, Sood MM. Amiodarone, Verapamil, or Diltiazem Use With Direct Oral Anticoagulants and the Risk of Hemorrhage in Older Adults. CJC Open 2022 Mar;4(3):315-323.
- 10.This information is based on an extract from the Certara Drug Interaction Database (DIDB) Platform, Copyright Certara 1999-2023..
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.